Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB

Ratings ESG MSCI

Ratings Abbott Laboratories: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company has a good ESG score relative to its sector, according to MSCI.
Highlights: Abbott Laboratories
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's high margin levels account for strong profits.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses: Abbott Laboratories
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The company benefits from high valuations in earnings multiples.
  • The company's enterprise value to sales, at 3.54 times its current sales, is high.
  • The company appears highly valued given the size of its balance sheet.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Rating Financials

Abbott Laboratories SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Abbott Laboratories SectorUnited States

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Abbott Laboratories SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Abbott Laboratories SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Abbott Laboratories SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
167B
BBB
106B
BBB
58.09B
AA
52.7B
AAA
42.86B
A
36.15B -
27.93B
BBB
25.27B
AA
20.79B
AAA
-
20.84B
AA
Average 55.75B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. ABT Stock
  4. Ratings Abbott Laboratories